Fu-Ming Zhou, Ph.D.

Fu-Ming Zhou, Ph.D.

Professor
Department of Pharmacology


The University of Tennessee Health Science Center
874 Union Avenue
Memphis, TN 38163
Phone: (901) 448-1779
Lab: 315 Crowe Building
Email: Fu-Ming Zhou

 

Education

  • Ph.D. Institution: Department of Physiology and Biophysics, University of Alabama at Birmingham
  • Postdoctoral: Department of Neurobiology, University of Alabama at Birmingham

Link

Pharmacology - Fu-Ming Zhou

Research Interests

Dr. Zhou currently conducts a multidisciplinary research program designed to determine the molecular, cellular and neuropharmacological mechanisms of the brain monoamine systems. Particular attention is being paid to the contributions of these monoamine systems to neuropsychiatric disorders such as Parkinson's disease, depression, schizophrenia, drug abuse, and attention deficit hyperactivity disorder (ADHD). We use rodents as our experimental animals. Mutant mice are used in specific cases.

Several techniques are used in the laboratory:

  1. Electrophysiology-patch clamp
  2. Molecular biology (single cell RT-PCR in combination with patch clamp; gene expression profiling and manipulation)
  3. Electrochemistry (fast cyclic voltammetry at the carbon fiber microelectrode; HPLC)
  4. Immunohistochemistry (double and triple immunolabeling, confocal microscopy)

Funding

Dr. Zhou's research is funded by R01 grants from the National Institute on Drug Abuse and National Institute of Mental Health and grants from private foundations.

Zhou BG Brain

Representative Publications

  • Chen GH, Li XL, Deng YQ, Zhou FM, Zou WQ, Jiang WX, Shangguan SQ, Lu ZN. The Molecular Mechanism of EPO Regulates the Angiogenesis after Cerebral Ischemia through AMPK-KLF2 Signaling Pathway. Crit Rev Eukaryot Gene Expr. 2019;29(2):105-112. doi: 10.1615/CritRevEukaryotGeneExpr.2019029018. PubMed PMID: 31679265.
  • Sun YL, Zhou FM, Wang HR. Mechanism of pomegranate ellagic polyphenols reducing insulin resistance on gestational diabetes mellitus rats. Am J Transl Res. 2019 Sep 15;11(9):5487-5500. eCollection 2019. PubMed PMID: 31632524; PubMed Central PMCID: PMC6789248.
  • Qiu JG, Wang L, Liu WJ, Wang JF, Zhao EJ, Zhou FM, Ji XB, Wang LH, Xia ZK, Wang W, Lin MC, Liu LZ, Huang YX, Jiang BH. Apigenin Inhibits IL-6 Transcription and Suppresses Esophageal Carcinogenesis. Front Pharmacol. 2019 Sep 11;10:1002. doi: 10.3389/fphar.2019.01002. eCollection 2019. PubMed PMID: 31572184; PubMed Central PMCID: PMC6749068.
  • Wang L, Qiu JG, He J, Liu WJ, Ge X, Zhou FM, Huang YX, Jiang BH, Liu LZ. Suppression of miR-143 contributes to overexpression of IL-6, HIF-1α and NF-κB p65 in Cr(VI)-induced human exposure and tumor growth. Toxicol Appl Pharmacol. 2019 Sep 1;378:114603. doi: 10.1016/j.taap.2019.114603. Epub 2019 May 29. PubMed PMID: 31152816.
  • Wang Q, Zhou FM. cAMP-producing chemogenetic and adenosine A2a receptor activation inhibits the inwardly rectifying potassium current in striatal projection neurons. Neuropharmacology. 2019 Apr;148:229-243. doi: 10.1016/j.neuropharm.2019.01.014. Epub 2019 Jan 16. PubMed PMID: 30659840.
  • Zhang YQ, Lan X, Zhang J, Zhou R, Dai ZY, Wu C, Bao YH, Yang LQ, Zhou FM, Zhao RP, Zeng G. [Association between gestational weight gain and adverse pregnancy outcomes: a prospective study]. Zhonghua Liu Xing Bing Xue Za Zhi. 2018 Dec 10;39(12):1626-1629. doi: 10.3760/cma.j.issn.0254-6450.2018.12.017. Chinese. PubMed PMID: 30572390.

View more references (pubmed link)